Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.

Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP.

Hematol Oncol. 2019 Aug 5. doi: 10.1002/hon.2662. [Epub ahead of print]

PMID:
31385336
2.

Comparison of methodologies for the detection of BRAF mutations in bone marrow trephine specimens.

Cardus B, Colling R, Hamblin A, Soilleux E.

J Clin Pathol. 2019 Jun;72(6):406-411. doi: 10.1136/jclinpath-2019-205734. Epub 2019 Mar 14.

PMID:
30872385
3.

Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.

Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, McGowan S, Hamblin A, Sousos N, Barkas N, Giustacchini A, Psaila B, Jacobsen SEW, Thongjuea S, Mead AJ.

Mol Cell. 2019 Mar 21;73(6):1292-1305.e8. doi: 10.1016/j.molcel.2019.01.009. Epub 2019 Feb 12.

4.

The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions.

Netelenbos T, Massey E, de Wreede LC, Harding K, Hamblin A, Sekhar M, Li A, Ypma PF, Ball L, Zwaginga JJ, Stanworth SJ.

Transfusion. 2019 Jan;59(1):160-168. doi: 10.1111/trf.14994. Epub 2018 Nov 1.

PMID:
30383912
5.

Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience.

Wedden S, Miller K, Frayling IM, Thomas T, Chefani A, Miller K, Hamblin A, Taylor JC, D'Arrigo C.

Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):e54-e62. doi: 10.1097/PAI.0000000000000631.

PMID:
29985199
6.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

7.

The 100 000 Genomes Project: bringing whole genome sequencing to the NHS.

Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, Halai D, Baple E, Craig C, Hamblin A, Henderson S, Patch C, O'Neill A, Devereau A, Smith K, Martin AR, Sosinsky A, McDonagh EM, Sultana R, Mueller M, Smedley D, Toms A, Dinh L, Fowler T, Bale M, Hubbard T, Rendon A, Hill S, Caulfield MJ; 100 000 Genomes Project.

BMJ. 2018 Apr 24;361:k1687. doi: 10.1136/bmj.k1687. No abstract available. Erratum in: BMJ. 2018 May 2;361:k1952. Devereaux A [corrected to Devereau A].

PMID:
29691228
8.

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.

Schuh A, Dreau H, Knight SJL, Ridout K, Mizani T, Vavoulis D, Colling R, Antoniou P, Kvikstad EM, Pentony MM, Hamblin A, Protheroe A, Parton M, Shah KA, Orosz Z, Athanasou N, Hassan B, Flanagan AM, Ahmed A, Winter S, Harris A, Tomlinson I, Popitsch N, Church D, Taylor JC.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002279. doi: 10.1101/mcs.a002279. Print 2018 Apr.

9.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.

10.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.

11.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 Jul;52(7):1082. doi: 10.1038/bmt.2017.87.

PMID:
28677683
12.

Physiological thermal limits predict differential responses of bees to urban heat-island effects.

Hamblin AL, Youngsteadt E, López-Uribe MM, Frank SD.

Biol Lett. 2017 Jun;13(6). pii: 20170125. doi: 10.1098/rsbl.2017.0125.

13.

Connected Care: improving outcomes for adults with serious mental illness.

Schuster JM, Kinsky SM, Kim JY, Kogan JN, Hamblin A, Nikolajski C, Lovelace J.

Am J Manag Care. 2016 Oct;22(10):678-682.

14.

Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

Hamblin A, Greenfield DM, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A, Shaw BE, Snowden JA.

Bone Marrow Transplant. 2017 Jun;52(6):889-894. doi: 10.1038/bmt.2017.67. Epub 2017 Apr 24.

15.

Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.

Hamblin A, Wordsworth S, Fermont JM, Page S, Kaur K, Camps C, Kaisaki P, Gupta A, Talbot D, Middleton M, Henderson S, Cutts A, Vavoulis DV, Housby N, Tomlinson I, Taylor JC, Schuh A.

PLoS Med. 2017 Feb 14;14(2):e1002230. doi: 10.1371/journal.pmed.1002230. eCollection 2017 Feb.

16.

Integrating health care for high-need medicaid beneficiaries with serious mental illness and chronic physical health conditions at managed care, provider, and consumer levels.

Kim JY, Higgins TC, Esposito D, Hamblin A.

Psychiatr Rehabil J. 2017 Jun;40(2):207-215. doi: 10.1037/prj0000231. Epub 2017 Feb 9.

PMID:
28182472
17.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Miller PDE, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA.

Bone Marrow Transplant. 2017 May;52(5):775-777. doi: 10.1038/bmt.2016.362. Epub 2017 Jan 23. No abstract available. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1082.

18.

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Guièze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, Nguyen-Khac F, Davi F, Véronèse L, Combes P, Le Garff-Tavernier M, Leblond V, Merle-Béral H, Alsolami R, Hamblin A, Mason J, Pettitt A, Hillmen P, Taylor J, Knight SJ, Tournilhac O, Schuh A.

Blood. 2015 Oct 29;126(18):2110-7. doi: 10.1182/blood-2015-05-647578. Epub 2015 Aug 27.

19.

Medicaid expansion: considerations for states regarding newly eligible jail-involved individuals.

Somers SA, Nicolella E, Hamblin A, McMahon SM, Heiss C, Brockmann BW.

Health Aff (Millwood). 2014 Mar;33(3):455-61. doi: 10.1377/hlthaff.2013.1132.

PMID:
24590945
20.

Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.

King BC, Hamblin AD, Savage PM, Douglas LR, Hansen TH, French RR, Johnson PW, Glennie MJ.

Cancer Immunol Immunother. 2013 Jun;62(6):1093-105. doi: 10.1007/s00262-013-1408-8. Epub 2013 Apr 19.

22.
23.

Inheritance of Resistance to Aflatoxin Production in the Cross Between Corn Inbreds B73 and LB31.

Campbell KW, Hamblin AM, White DG.

Phytopathology. 1997 Nov;87(11):1144-7. doi: 10.1094/PHYTO.1997.87.11.1144.

24.

Inheritance of resistance to Aspergillus ear rot and aflatoxin production of corn from tex6.

Hamblin AM, White DG.

Phytopathology. 2000 Mar;90(3):292-6. doi: 10.1094/PHYTO.2000.90.3.292.

25.

Searching for a business case for quality in Medicaid managed care.

Greene SB, Reiter KL, Kilpatrick KE, Leatherman S, Somers SA, Hamblin A.

Health Care Manage Rev. 2008 Oct-Dec;33(4):350-60. doi: 10.1097/01.HCM.0000318772.59771.b2.

PMID:
18815500
26.

The immunodeficiency of chronic lymphocytic leukaemia.

Hamblin AD, Hamblin TJ.

Br Med Bull. 2008;87:49-62. doi: 10.1093/bmb/ldn034. Epub 2008 Aug 27. Review.

PMID:
18755702
27.

Challenges to using a business case for addressing health disparities.

Lurie N, Somers SA, Fremont A, Angeles J, Murphy EK, Hamblin A.

Health Aff (Millwood). 2008 Mar-Apr;27(2):334-8. doi: 10.1377/hlthaff.27.2.334.

PMID:
18332487
28.

Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia.

Hamblin AD, Hamblin TJ.

Expert Opin Ther Targets. 2005 Dec;9(6):1165-78. Review.

PMID:
16300468
29.

Biochemical and functional assessment of equine lymphocyte phosphodiesterases and protein kinase C.

Rickards KJ, Page CP, Hamblin AS, Goode NT, Cunningham FM.

Vet Immunol Immunopathol. 2004 Apr;98(3-4):153-65.

PMID:
15010224
30.

Role of the chemokine eotaxin in the pathogenesis of equine sweet itch.

Benarafa C, Collins ME, Hamblin AS, Cunningham FM.

Vet Rec. 2002 Dec 7;151(23):691-3.

PMID:
12503787
31.

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.

Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC.

J Biol Chem. 2003 Feb 21;278(8):5794-801. Epub 2002 Dec 12.

32.

Characterisation of the biological activity of recombinant equine eotaxin in vitro.

Benarafa C, Collins ME, Hamblin AS, Sabroe I, Cunningham FM.

Cytokine. 2002 Jul 7;19(1):27-30.

PMID:
12200110
33.
34.

Autoreactivity in collagen-induced arthritis of rats: a potential role for T cell responses to self MHC peptides.

Catchpole B, Ward FJ, Hamblin AS, Staines NA.

J Autoimmun. 2002 Jun;18(4):271-80.

PMID:
12144808
35.

Modulating immune responses with dendritic cells: an attainable goal in veterinary medicine?

Vecchione A, Catchpole B, D'Mello F, Kanellos T, Hamblin A.

Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):215-21.

PMID:
12072237
36.

Autologous mixed lymphocyte responses in experimentally-induced arthritis of the Lewis rat.

Catchpole B, Hamblin AS, Staines NA.

Autoimmunity. 2002 Mar;35(2):111-7.

PMID:
12071434
37.

Production and characterisation of monoclonal antibodies specific for chicken interleukin-2.

Rothwell L, Hamblin A, Kaiser P.

Vet Immunol Immunopathol. 2001 Dec;83(3-4):149-60.

PMID:
11730926
38.

T cell lines generated with type II collagen proliferate in an autologous mixed lymphocyte response.

Catchpole B, Hamblin AS, Staines NA.

J Autoimmun. 2001 Nov;17(3):181-9.

PMID:
11712855
39.

Training in international animal health.

Short N, Hamblin A.

Vet Rec. 2001 Oct 13;149(15):462. No abstract available.

PMID:
11688752
40.

Antigen presentation of Type II collagen in rats.

Catchpole B, Staines NA, Hamblin AS.

Clin Exp Immunol. 2001 Sep;125(3):478-84.

41.

The anti-human CD21 antibody, BU33, identifies equine B cells.

Mayall S, Siedek E, Hamblin AS.

J Comp Pathol. 2001 Jan;124(1):83-7.

PMID:
11428193
42.
44.

Immunogenetic analysis reveals that epitope shifting occurs during B-cell affinity maturation in primary biliary cirrhosis.

Potter KN, Thomson RK, Hamblin A, Richards SD, Lindsay JG, Stevenson FK.

J Mol Biol. 2001 Feb 9;306(1):37-46.

PMID:
11178892
45.

Cloning of equine chemokines eotaxin, monocyte chemoattractant protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and induction by IL-4 in dermal fibroblasts.

Benarafa C, Cunningham FM, Hamblin AS, Horohov DW, Collins ME.

Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):283-98.

PMID:
11044560
46.

Equine macrophage identification with an antibody (Ki-M6) to human CD68 and a new monoclonal antibody (JB10).

Siedek EM, Honnah-Symns N, Fincham SC, Mayall S, Hamblin AS.

J Comp Pathol. 2000 Feb-Apr;122(2-3):145-54.

PMID:
10684683
47.

Characterisation of lymphocyte subpopulations in the skin and circulation of horses with sweet itch (Culicoides hypersensitivity).

McKelvie J, Foster AP, Cunningham FM, Hamblin AS.

Equine Vet J. 1999 Nov;31(6):466-72.

PMID:
10596926
48.

Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish.

Kanellos TS, Sylvester ID, Butler VL, Ambali AG, Partidos CD, Hamblin AS, Russell PH.

Immunology. 1999 Apr;96(4):507-10.

49.

Epithelial lymphocyte and macrophage distribution in the adult and fetal equine lung.

Banks EM, Kyriakidou M, Little S, Hamblin AS.

J Comp Pathol. 1999 Jan;120(1):1-13.

PMID:
10098012
50.

Supplemental Content

Loading ...
Support Center